Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.38 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL384300 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4YTHDC1SLC6A3KMT2A | |
| SCHEMBL384299 | 1.00 | SLC6A2 (0.49) | SLC6A2SLC6A4YTHDC1SLC6A3KMT2A | |
| SCHEMBL28018410 | 0.90 | YTHDC1 (0.43) | SLC6A2SLC6A4YTHDC1SLC6A3KMT2A | |
| SCHEMBL26038459 | 0.90 | YTHDC1 (0.43) | SLC6A2SLC6A4YTHDC1SLC6A3KMT2A | |
| SCHEMBL28018409 | 0.90 | YTHDC1 (0.43) | SLC6A2SLC6A4YTHDC1SLC6A3KMT2A | |
| SCHEMBL26038458 | 0.90 | YTHDC1 (0.43) | SLC6A2SLC6A4YTHDC1SLC6A3KMT2A | |
| SCHEMBL3376962 | 0.87 | YTHDC1 (0.58) | SLC6A2SLC6A4YTHDC1SLC6A3KMT2A | |
| SCHEMBL15689071 | 0.84 | SLC6A2 (0.43) | SLC6A2SLC6A4YTHDC1SLC6A3KMT2A | |
| SCHEMBL20223877 | 0.84 | SLC6A2 (0.43) | SLC6A2SLC6A4YTHDC1SLC6A3KMT2A | |
| SCHEMBL7921383 | 0.83 | YTHDC1 (0.45) | SLC6A2SLC6A4YTHDC1SLC6A3KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10370375-B2 | Heterocyclyl-substituted cyclohexylsulfonamides as JAK inhibitors | ELANCO TIERGESUNDHEIT AG (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180346465-A1 | New Compounds | ELANCO TIERGESUNDHEIT AG (US) | 2018-12-06 | — | — | US | disclosed |
| EP-3122731-B1 | CYCLOHEXYLMETHANSULFONAMIDES | ELANCO TIERGESUNDHEIT AG (CH) | 2018-10-10 | — | — | EP | disclosed |
| US-10059709-B2 | Compounds | ELANCO TIERGESUNDHEIT AG (CH) | 2018-08-28 | — | — | US | disclosed |
| EP-2457913-B1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARM LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2090577-B1 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20170050965-A1 | New Compounds | ELANCO TIERGESUNDHEIT AG (CH) | 2017-02-23 | — | — | US | disclosed |
| EP-3122731-A1 | NEW COMPOUNDS | Novartis Tiergesundheit AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015144773-A1 | NEW COMPOUNDS | NOVARTIS TIERGESUNDHEIT AG (CH) | 2015-10-01 | — | — | WO | disclosed |
| EP-2924026-A1 | Aminosulfonylmethylcyclohexanes as JAK inhibitors | Novartis Tiergesundheit AG (CH) | 2015-09-30 | — | — | EP | disclosed |
| EP-2457913-A2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2078016-B1 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-06 | — | — | US | disclosed |
| US-7981893-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-07-19 | — | — | US | disclosed |
| EP-2307377-A1 | NICOTINAMIDE DERIVATIVES | Pfizer Limited (GB) | 2011-04-13 | — | — | EP | disclosed |
| WO-2009153720-A1 | NICOTINAMIDE DERIVATIVES | PFIZER LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180346465-A1 | New Compounds | HLA-DRB1, SLC10A1, NFATC1 | SLC6A2 1934/4885SLC6A4 1727/4885YTHDC1 4357/4885 |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | SLC6A2 2558/4885SLC6A4 1592/4885YTHDC1 4368/4885 |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | JAK2, GLS2, NFKBIA | SLC6A2 4603/4885SLC6A4 4618/4885YTHDC1 4263/4885 |
| US-10370375-B2 | Heterocyclyl-substituted cyclohexylsulfonamides as JAK inhibitors | JAK1, JAK3, JAK2 | SLC6A2 3819/4885SLC6A4 3301/4885YTHDC1 3534/4885 |
| US-20170050965-A1 | New Compounds | HLA-DRB1, SLC10A1, NFATC1 | SLC6A2 1935/4885SLC6A4 1721/4885YTHDC1 4373/4885 |
| US-10059709-B2 | Compounds | HLA-DRB1, SLC10A1, ITCH | SLC6A2 1774/4885SLC6A4 1780/4885YTHDC1 4122/4885 |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | SLC6A2 4783/4885SLC6A4 4804/4885YTHDC1 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.